Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
Scientists at University of Ulsan detail research in angiogenesis
August 26th, 2008
In this recent report, researchers in Seoul, South Korea conducted a study "To evaluate the potential effect of bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), on the angiogenesis and tumor growth of retinoblastoma in vitro and in vivo. The antiangiogenic effects of bevacizumab were evaluated in a coculture of a Y-79 human retinoblastoma cell line and a human umbilical vein endothelial cell line by means of a cell proliferation assay kit and a VEGF enzyme-linked immunosorbent assay." "The Y-79 xenotransplanted nude mice were treated with bevacizumab intraperitoneally twice weekly for 4 weeks, during which each tumor was measured...
Source: Cancer Weekly (2008-08-26)
|
